Friday, December 4, 2020

Tag: Medical

Emerging Growth Medical Company

Tonix Pharmaceuticals (TNXP) Could Be a Come-From-Behind Vaccine Shocker

Among small-capitalization companies in the Covid-19 race, Tonix Pharmaceuticals (NASDAQ:TNXP) may be worth consideration with what I would term “dumb money.” Currently, TNXP stock is trading hands for less than a buck, which immediately tells you something about this opportunity’s risk profile.

A low float Biotech that’s ahead of the Curve; Focus on...

Back in July, the stock was given a target price of between $1.74 and $2.32 per share by Marble Arch Research. You can download the full report here: - Among other results, the report states “At ~1x FY23 sales, the stock is substantially undervalued relative to its comps mostly trading in a comparable 3X-4X P/S multiple range.”

BioLife Sciences (BLFE) Announces Immediate Commercial Availability of a 10-Minute, Ultra-Rapid,...

Miami, FL – October 26, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging...

Can B’s (CANB) Director and CFO, Stanley Teeple, to Update on...

In the podcast, Mr. Teeple will discuss the current state of Can B Corp, along with its subsidiaries, new product launches, its FDA approved medical device and its strong medical advisory team.

A niche company in biotech could prove to be the biggest...

Recently trading at around .70 per share, PetVivo Holdings, Inc. (OTCQB: PETV) just announced something interesting on Tuesday which brought a $1.40 share price and what could be the beginning of a strong accumulation of their stock.

Can B Corp. (OTCQB: CANB) Partners with Dr. Karl Zarse to...

Miami, FL –October 22, 2020, 2020 (EmergingGrowth.com NewsWire) — EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for...

Cannabics Pharmaceuticals (CNBX) Prepares to Submit the FDA with a pre-IND...

Cannabics Pharmaceuticals (CNBX) Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33

Why InflaRx (IFRX) Could Piggyback Off Regeneron’s Sudden Interest

After the initial deadly volley from the novel coronavirus, the broader healthcare industry’s attention shifted from developing treatments to researching and developing vaccines. Not...

PAO Group, Inc. (PAOG) FDA Application Process For Respiratory Cannabis Drug...

PAO Group, Inc. (PAOG) FDA Application Process For Respiratory Cannabis Drug Treatment Update Scheduled This Friday

MATEON’S (MATN) PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST...

MATEON’S (MATN) PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN ARGENTINA